Multiple Myeloma Advances Spotlighted at IMS Meeting in Glasgow

A review in Haematologica outlines the significance of the t(11;14) translocation, present in 15‑20% of multiple myeloma patients, as a key biomarker that drives dependence on the pro‑survival BCL2 protein. The article notes that BCL2‑inhibitors can target this pathway, offering a biomarker‑driven treatment option for a disease that remains incurable despite recent therapeutic gains.

The International Myeloma Society’s annual meeting in Glasgow will convene over 3,000 clinicians and scientists from 75 countries to discuss the latest advances. Themes include treatment of newly diagnosed patients, strategies for first relapse, blood‑based diagnostics, and immune‑system monitoring. Prof Nikhil C. Munshi said, “Amazing progress in myeloma has taken place and is expected over the next year,” adding that the meeting will help “define what would curing myeloma look like.” The agenda also features talks on AI in medicine and industry symposia supported by major pharmaceutical partners.